NovaBridge Biosciences Cash And Cash Equivalents At Carrying Value

Quick Answer

NovaBridge Biosciences reported Cash And Cash Equivalents At Carrying Value of $68.26 million for the year ending 2024.

  • NovaBridge Biosciences showed a decrease of -76.6% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
  • This data is from NovaBridge Biosciences's annual report (Form 10-K), filed with the SEC on April 3, 2025.
  • XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2018 to 2024), NovaBridge Biosciences's Cash And Cash Equivalents At Carrying Value has declined by 95.7%.
  • Historical annual values: Fiscal year 2024: $68.26 million | Fiscal year 2023: $291.51 million | Fiscal year 2022: $342.92 million | Fiscal year 2021: $3.52 billion | Fiscal year 2020: $4.76 billion | Fiscal year 2019: $1.14 billion | Fiscal year 2018: $1.59 billion.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: